Improvement in social competence with short-term atypical antipsychotic treatment

A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning

Philip D Harvey, Thomas L. Patterson, Larry S. Potter, Kate Zhong, Martin Brecher

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. Method: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period. Results: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. Conclusions: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.

Original languageEnglish
Pages (from-to)1918-1925
Number of pages8
JournalAmerican Journal of Psychiatry
Volume163
Issue number11
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Risperidone
Cognition
Antipsychotic Agents
Neuropsychological Tests
Mental Competency
Schizophrenia
Therapeutics
Outcome Assessment (Health Care)
Social Skills
Quetiapine Fumarate
Clinical Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{0fa7afc0a4864bb49e5fe086b6608705,
title = "Improvement in social competence with short-term atypical antipsychotic treatment: A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning",
abstract = "Objective: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. Method: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period. Results: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. Conclusions: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.",
author = "Harvey, {Philip D} and Patterson, {Thomas L.} and Potter, {Larry S.} and Kate Zhong and Martin Brecher",
year = "2006",
month = "11",
day = "1",
doi = "10.1176/appi.ajp.163.11.1918",
language = "English",
volume = "163",
pages = "1918--1925",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "11",

}

TY - JOUR

T1 - Improvement in social competence with short-term atypical antipsychotic treatment

T2 - A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning

AU - Harvey, Philip D

AU - Patterson, Thomas L.

AU - Potter, Larry S.

AU - Zhong, Kate

AU - Brecher, Martin

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Objective: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. Method: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period. Results: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. Conclusions: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.

AB - Objective: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. Method: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (dose range: 2-8 mg/day) for an 8-week period. Results: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. Conclusions: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33751325623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751325623&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.11.1918

DO - 10.1176/appi.ajp.163.11.1918

M3 - Article

VL - 163

SP - 1918

EP - 1925

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 11

ER -